Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).

NCT00434213 is registered in ClinicalTrials.gov with Noven Therapeutics as lead sponsor.

NCT NCT00434213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00434213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).
Lead sponsor
Noven Therapeutics
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2007
Completion date
July 31, 2008
Enrollment
309 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder